McWin Capital Partners, has invested in Nuritas, a Dublin-based biotechnology company.
The funding was part of their oversubscribed €40m Series C funding round.
McWin is investing alongside M&G’s Catalyst Capital Fund, a £5bn evergreen vehicle focused on growth-stage companies in health, climate, and enabling technologies.
Together, the firms say their aim is to help Nuritas scale sales, expand their product portfolio and grow their team.
Grosvenor and ECBF also joined the funding round.
Founded in 2014, Nuritas is currently backed by a number of other investors, including Cleveland Avenue.
The company also has some notable angel investors, including U2’s Bono and The Edge, and Salesforce.com’s Marc Benioff.
It has developed a proprietary AI platform – powered by proprietary data and genomics, which is used to discover and develop a range of holistic products known as bioactive peptides.
The peptides can then be integrated into food, supplements, cosmetics, and other products as functional ingredients.
The bioactive peptides developed by Nuritas have …